INS and type 2 diabetes mellitus: In T2DM patients, once-daily administrationof dapagliflozin forseveral weeks (2–24 weeks) resulted in the reduction of bothfasting/postprandial glycemia and HbA1c levels, enhanced insulin sensitivity,and, on the whole, improved glycemic control, without significantrisk of hypoglycemia or renal damage.67−70